SCHEMBL24330744

SCHEMBL24330744

Cn1ccc(C(=O)Nc2nc(-c3ccncc3)cs2)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.57
▸ ROCK1 Q13464 10/20 0.57
▸ MEN1 O00255 3/20 0.54
▸ KMT2A Q03164 3/20 0.54
▸ MAPT P10636 3/20 0.54
▸ POLB P06746 1/20 0.54
▸ CLK1 P49759 1/20 0.54
▸ MCL1 Q07820 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54
▸ LMNA P02545 2/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ MITF O75030 1/20 0.53
▸ NTSR1 P30989 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ CDC25A P30304 1/20 0.52
▸ CDC25B P30305 1/20 0.52
▸ CDC25C P30307 1/20 0.52
▸ HTT P42858 1/20 0.52
▸ THRB P10828 1/20 0.52
▸ ROCK2 O75116 5/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26658235 0.89 LMNA (0.59) MEN1KMT2AMAPTPOLBHSD17B10
SCHEMBL26884180 0.88 KMT2A (0.61) ROCK1MEN1KMT2AMAPTLMNA
SCHEMBL26884172 0.88 MEN1 (0.54) ROCK1MEN1KMT2AMAPTPOLB
SCHEMBL24329679 0.86 MEN1 (0.62) ROCK1MEN1KMT2AMAPTPOLB
SCHEMBL24329676 0.85 MAPT (0.53) ROCK1MEN1KMT2AMAPTPOLB
SCHEMBL24329836 0.83 MAPT (0.50) ROCK1MEN1KMT2AMAPTPOLB
SCHEMBL24329677 0.82 L3MBTL1 (0.67) MEN1KMT2AMAPTPOLBHSD17B10
SCHEMBL26884174 0.82 HDAC3 (0.53) ROCK1MEN1KMT2AMAPTHSD17B10
SCHEMBL26884220 0.80 SMN1; SMN2 (0.48) MEN1KMT2AMAPTPOLBHSD17B10
SCHEMBL26884178 0.80 KMT2A (0.47) MEN1KMT2AMAPTPOLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
WO-2022082071-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF US THEREOF CARTHRONIX, INC. (US) 2022-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF STAT1, STAT3, STAT6 PARP1 4773/4885ROCK1 2053/4885MEN1 4814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback